Tandem Diabetes Care Reports 2018 Financial Results and 2019 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Tandem Diabetes (TNDM) Tops Q4 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
February 26, 2019 4:11 PM ESTTandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.02, $0.22 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $76.2 million versus the consensus estimate of $56.34 million.
2018 was both extraordinary and transformative for our Company, as we entered the year fighting for a... More
